{"pmid":32369606,"title":"COVID-19 Infection and Sickle Cell Disease: A UK Centre Experience.","text":["COVID-19 Infection and Sickle Cell Disease: A UK Centre Experience.","During the COVID-19 pandemic, patients with sickle cell disease (SCD) have been included in the \"high risk\" group of the population. This is due to their impaired immunity resulting from functional hyposplenism, systemic vasculopathy that predisposes them to end organ dysfunction, and a high risk of thrombosis (Ware et al, 2017).","Br J Haematol","McCloskey, Kayleigh A","Meenan, John","Hall, Rhys","Tsitsikas, Dimitris A","32369606"],"abstract":["During the COVID-19 pandemic, patients with sickle cell disease (SCD) have been included in the \"high risk\" group of the population. This is due to their impaired immunity resulting from functional hyposplenism, systemic vasculopathy that predisposes them to end organ dysfunction, and a high risk of thrombosis (Ware et al, 2017)."],"journal":"Br J Haematol","authors":["McCloskey, Kayleigh A","Meenan, John","Hall, Rhys","Tsitsikas, Dimitris A"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369606","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16779","locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Diagnosis","Treatment","Prevention"],"weight":1,"_version_":1666138496207683586,"score":9.490897,"similar":[{"pmid":32420608,"title":"Patients with Sickle cell disease and suspected COVID-19 in a pediatric ICU.","text":["Patients with Sickle cell disease and suspected COVID-19 in a pediatric ICU.","Concern has been raised on sickle cell disease (SCD) patients and the new viral infection with SARS-COV-2 since SCD patients are particularly prone to infectious diseases and acute chest syndrome (ACS). Although case reports have been published to describe COVID-19 related ACS in adult patients (1-4), pediatric data are lacking.","Br J Haematol","Heilbronner, C","Berteloot, L","Tremolieres, P","Dupic, L","De Saint Blanquat, L","Lesage, F","Odievre, M H","de Marcellus, C","Fourgeaud, J","de Montalembert, M","Grimaud, M","Moulin, F","Renolleau, S","Allali, S","Oualha, M","32420608"],"abstract":["Concern has been raised on sickle cell disease (SCD) patients and the new viral infection with SARS-COV-2 since SCD patients are particularly prone to infectious diseases and acute chest syndrome (ACS). Although case reports have been published to describe COVID-19 related ACS in adult patients (1-4), pediatric data are lacking."],"journal":"Br J Haematol","authors":["Heilbronner, C","Berteloot, L","Tremolieres, P","Dupic, L","De Saint Blanquat, L","Lesage, F","Odievre, M H","de Marcellus, C","Fourgeaud, J","de Montalembert, M","Grimaud, M","Moulin, F","Renolleau, S","Allali, S","Oualha, M"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420608","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16802","keywords":["covid-19","acute chest syndrome","children","intensive care","sickle cell disease"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667159284382695424,"score":203.59131},{"pmid":32314798,"title":"COVID-19 Infection in Patients with Sickle Cell Disease.","text":["COVID-19 Infection in Patients with Sickle Cell Disease.","Severe acute respiratory syndrome coronavirus 2, also known as COVID-19, has spread to 184 countries with almost 1.5 million cases as of mid-April 2020 since first reported (1). The clinical features of this disease are not completely understood, however severe illness is thought to predominantly occur in adults with advanced age and those with underlying comorbidities (2). Sickle cell disease (SCD), an immunocompromised condition, puts patients at higher risk for respiratory infections and subsequent pulmonary complications such as acute chest syndrome (ACS) (3).","Br J Haematol","Hussain, Faiz A","Njoku, Franklin U","Saraf, Santosh L","Molokie, Robert E","Gordeuk, Victor R","Han, Jin","32314798"],"abstract":["Severe acute respiratory syndrome coronavirus 2, also known as COVID-19, has spread to 184 countries with almost 1.5 million cases as of mid-April 2020 since first reported (1). The clinical features of this disease are not completely understood, however severe illness is thought to predominantly occur in adults with advanced age and those with underlying comorbidities (2). Sickle cell disease (SCD), an immunocompromised condition, puts patients at higher risk for respiratory infections and subsequent pulmonary complications such as acute chest syndrome (ACS) (3)."],"journal":"Br J Haematol","authors":["Hussain, Faiz A","Njoku, Franklin U","Saraf, Santosh L","Molokie, Robert E","Gordeuk, Victor R","Han, Jin"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314798","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bjh.16734","topics":["Case Report"],"weight":1,"_version_":1666138493470900225,"score":178.44891},{"pmid":32501731,"title":"Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV-2?","text":["Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV-2?","The pandemic of coronavirus disease 2019 (COVID-19) has become a global threat to public health. Functional impairments in multiple organs have been reported in COVID-19 including lungs, heart, kidney, liver, brain and vascular system. Patients with metabolic-associated preconditions such as hypertension, obesity and diabetes are susceptible to experience severe symptoms. The recent emerging evidence of coagulation disorders in COVID-19 suggests that vasculopathy appears to be an independent risk factor promoting disease severity and mortality of affected patients. We have recently found that the decreased levels of low-density lipoprotein cholesterols (LDL-c) correlate with disease severity in COVID-19 patients, indicating pathological interactions between dyslipidemia and vasculopothy in COVID-19 patients. However, this clinical manifestation has been unintentionally underestimated by physicians and scientific communities. As metabolic-associated morbidities are generally accompanied with endothelial cell (EC) dysfunctions, these pre-existing conditions may make ECs more vulnerable to SARS-CoV-2 attack. In this mini-review, we summarize the metabolic and vascular manifestations of COVID-19 with an emphasis on the association between changes in LDL-c levels and the development of severe symptoms as well as the pathophysiologic mechanisms underlying the synergistic effect of LDL-c and SARS-CoV-2 on EC injuries and vasculopathy.","Am J Physiol Endocrinol Metab","Cao, Xiaoling","Yin, Rong","Albrecht, Helmut","Fan, Daping","Tan, Wenbin","32501731"],"abstract":["The pandemic of coronavirus disease 2019 (COVID-19) has become a global threat to public health. Functional impairments in multiple organs have been reported in COVID-19 including lungs, heart, kidney, liver, brain and vascular system. Patients with metabolic-associated preconditions such as hypertension, obesity and diabetes are susceptible to experience severe symptoms. The recent emerging evidence of coagulation disorders in COVID-19 suggests that vasculopathy appears to be an independent risk factor promoting disease severity and mortality of affected patients. We have recently found that the decreased levels of low-density lipoprotein cholesterols (LDL-c) correlate with disease severity in COVID-19 patients, indicating pathological interactions between dyslipidemia and vasculopothy in COVID-19 patients. However, this clinical manifestation has been unintentionally underestimated by physicians and scientific communities. As metabolic-associated morbidities are generally accompanied with endothelial cell (EC) dysfunctions, these pre-existing conditions may make ECs more vulnerable to SARS-CoV-2 attack. In this mini-review, we summarize the metabolic and vascular manifestations of COVID-19 with an emphasis on the association between changes in LDL-c levels and the development of severe symptoms as well as the pathophysiologic mechanisms underlying the synergistic effect of LDL-c and SARS-CoV-2 on EC injuries and vasculopathy."],"journal":"Am J Physiol Endocrinol Metab","authors":["Cao, Xiaoling","Yin, Rong","Albrecht, Helmut","Fan, Daping","Tan, Wenbin"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501731","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1152/ajpendo.00255.2020","keywords":["covid-19","ldl","sars-cov-2","thrombosis","vasculopathy"],"e_drugs":["Cholesterol"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668890966325460992,"score":105.81118},{"pmid":32330288,"title":"Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic.","text":["Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic.","With the developing COVID-19 pandemic (caused by the novel zoonotic SARS-CoV-2 coronavirus), the UK population are urged to follow Government advice on managing symptoms and reducing viral transmission (1). Unusually, patients with sickle cell anaemia (HbSS genotype) have been explicitly mentioned in this as a group at increased risk due to their non-functioning spleen (2). Unfortunately, there is no specific advice for patients with sickle cell disease of other genotypes, thalassaemia and other inherited anaemias. Many of these are at increased risk of fulminant bacterial infection, and therefore may erroneously self-isolate if their fever is mistakenly attributed to a viral cause, delaying potentially life-saving antibiotic therapy.","Br J Haematol","Roy, Noemi Ba","Telfer, Paul","Eleftheriou, Perla","de la Fuente, Josu","Drasar, Emma","Shah, Farrukh","Roberts, David","Atoyebi, Wale","Trompeter, Sara","Mark Layton, D","Lugthart, Sanne","Stuart-Smith, Sara","Chakravorty, Subarna","Wright, Josh","Porter, John","Inusa, Baba","Howard, Jo","32330288"],"abstract":["With the developing COVID-19 pandemic (caused by the novel zoonotic SARS-CoV-2 coronavirus), the UK population are urged to follow Government advice on managing symptoms and reducing viral transmission (1). Unusually, patients with sickle cell anaemia (HbSS genotype) have been explicitly mentioned in this as a group at increased risk due to their non-functioning spleen (2). Unfortunately, there is no specific advice for patients with sickle cell disease of other genotypes, thalassaemia and other inherited anaemias. Many of these are at increased risk of fulminant bacterial infection, and therefore may erroneously self-isolate if their fever is mistakenly attributed to a viral cause, delaying potentially life-saving antibiotic therapy."],"journal":"Br J Haematol","authors":["Roy, Noemi Ba","Telfer, Paul","Eleftheriou, Perla","de la Fuente, Josu","Drasar, Emma","Shah, Farrukh","Roberts, David","Atoyebi, Wale","Trompeter, Sara","Mark Layton, D","Lugthart, Sanne","Stuart-Smith, Sara","Chakravorty, Subarna","Wright, Josh","Porter, John","Inusa, Baba","Howard, Jo"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330288","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bjh.16687","locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138494587633664,"score":103.247765},{"pmid":32420949,"title":"Rare Anaemias, Sickle-Cell Disease and COVID-19.","text":["Rare Anaemias, Sickle-Cell Disease and COVID-19.","For rare haematological diseases (RHD), the first question to be answered is if patients with be- nign red blood cell (RBC) defects like haemoglobinopathies, membranopathies and enzymopathies are more vulnerable to COVID-19 infection. Up to now, there is no yet literature on the subject, but, like in general population, the presence of comorbidities such as diabetes, heart disease, pulmonary hypertension, reduced kidney and/or liver function, worsen the effects of the infection. Splenectomy may be an additional risk factor.","Acta Biomed","Vives Corrons, Joan-Lluis","De Sanctis, Vincenzo","32420949"],"abstract":["For rare haematological diseases (RHD), the first question to be answered is if patients with be- nign red blood cell (RBC) defects like haemoglobinopathies, membranopathies and enzymopathies are more vulnerable to COVID-19 infection. Up to now, there is no yet literature on the subject, but, like in general population, the presence of comorbidities such as diabetes, heart disease, pulmonary hypertension, reduced kidney and/or liver function, worsen the effects of the infection. Splenectomy may be an additional risk factor."],"journal":"Acta Biomed","authors":["Vives Corrons, Joan-Lluis","De Sanctis, Vincenzo"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420949","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.23750/abm.v91i2.9532","weight":0,"_version_":1667159284587167744,"score":91.87541}]}